Jonathan Kay to Rheumatic Diseases
This is a "connection" page, showing publications Jonathan Kay has written about Rheumatic Diseases.
Connection Strength
4.629
-
Reginato AM, Petri MA, Kay J. Walter Bauer, Marian Wilkins Ropes, and the Massachusetts General Hospital. Rheum Dis Clin North Am. 2024 02; 50(1):79-92.
Score: 0.853
-
Kay J. Are There Benefits and Risks to Biosimilars from a Patient Perspective? Rheum Dis Clin North Am. 2019 08; 45(3):465-476.
Score: 0.629
-
Kay J, Schoels MM, D?rner T, Emery P, Kvien TK, Smolen JS, Breedveld FC. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 02; 77(2):165-174.
Score: 0.558
-
D?rner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015 Dec; 11(12):713-24.
Score: 0.484
-
Kay J. Rheumatic rarities. Preface. Rheum Dis Clin North Am. 2013 May; 39(2):xv-xvi.
Score: 0.413
-
Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology--"O brave new world". Nat Rev Rheumatol. 2012 06 05; 8(7):430-6.
Score: 0.388
-
Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011 May 12; 13(3):112.
Score: 0.360
-
Lebiedz-Odrobina D, Kay J. Rheumatic manifestations of diabetes mellitus. Rheum Dis Clin North Am. 2010 Nov; 36(4):681-99.
Score: 0.347
-
Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Ann Rheum Dis. 2019 07; 78(7):872-878.
Score: 0.154
-
Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol. 2016 Jul-Aug; 34(4 Suppl 98):69-76.
Score: 0.129
-
D?rner T, Strand V, Cornes P, Gon?alves J, Gul?csi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016 06; 75(6):974-82.
Score: 0.126
-
Collier DS, Kay J, Estey G, Surrao D, Chueh HC, Grant RW. A rheumatology-specific informatics-based application with a disease activity calculator. Arthritis Rheum. 2009 Apr 15; 61(4):488-94.
Score: 0.078
-
Sarraf P, Kay J, Reginato AM. Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Curr Rheumatol Rep. 2008 Jul; 10(3):235-48.
Score: 0.074
-
Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE. The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. Clin Immunol. 2018 01; 186:87-93.
Score: 0.035